Omega-3 fatty acids, xanthophylls don't cut CVD risk

ω-3 fatty acids, xanthophylls don't cut CVD risk

(HealthDay)—Dietary supplementation with ω-3 polyunsaturated fatty acids or macular xanthophylls do not seem to reduce the risk of cardiovascular disease (CVD) in older adults with age-related macular degeneration, according to a study published online March 17 in JAMA Internal Medicine.

Denise E. Bonds, M.D., M.P.H., from the National Institutes of Health in Bethesda, Md., and colleagues examined whether supplementing diet with long-chain ω-3 or with macular xanthophylls was associated with the rate of CVD. A total of 4,203 participants from the Cardiovascular Outcome Study (aged 50 to 85 years) with in one eye, were recruited and randomized to receive daily supplementation with long-chain ω-3 polyunsaturated (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]), macular xanthophylls (lutein and zeaxanthin), combination of the two, or matching placebos. Participants were followed for a median of 4.8 years.

The researchers found that there were 459 cardiovascular events that met one of the study definitions for a CVD outcome. There was no reduction in the risk of CVD or secondary CVD outcomes for DHA + EPA (primary outcome: hazard ratio, 0.95; 95 percent confidence interval, 0.78 to 1.17) or lutein + zeaxanthin (primary outcome: hazard ratio, 0.94; 95 percent confidence interval, 0.77 to 1.15), in intention-to-treat analysis. There were no treatment group-related differences in or serious adverse events.

"Our results are consistent with a growing body of evidence from clinical trials that have found little CVD benefit from moderate levels of dietary supplementation," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Supplement aids age-related macular degeneration

date Mar 26, 2013

(HealthDay)—A supplement containing a combination of lutein, zeaxanthin, and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs) significantly benefits patients with age-related macular degeneration ...

Post-transplant, eGFR impacts cardio risk independently

date May 30, 2012

(HealthDay) -- In stable kidney transplant recipients, kidney function, as determined by estimated glomerular filtration rate (eGFR), is independently associated with cardiovascular (CVD) events and death, ...

Recommended for you

Cognitive impairment predicts worse outcome in heart failure

date May 24, 2015

Cognitive impairment predicts worse outcome in elderly heart failure patients, reveals research presented today at Heart Failure 2015 by Hiroshi Saito, a physiotherapist at Kameda Medical Centre in Kamogawa, Japan. Patients ...

1950s drug is future heart treatment

date May 22, 2015

Oxford University researchers have found a promising future treatment for heart disease, going back to a drug first developed in 1950.

Time is muscle in acute heart failure

date May 21, 2015

Urgent diagnosis and treatment in acute heart failure has been emphasised for the first time in joint recommendations published today in European Heart Journal.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.